Default DAPT Duration ≥ 12 Months Post ACS Strategy Tool

Clinical calculation support · Verify results before clinical use

Patient assessment

Review the factors that influence whether a 12-month dual antiplatelet therapy strategy is appropriate.

12 moDefault course

Use a formal assessment where appropriate, such as ARC-HBR criteria. “Uncertain” should not be treated as confirmed low bleeding risk.

Examples include atrial fibrillation with an indication for anticoagulation or another established indication.

Select the principal treatment pathway for the index event.

This factor informs reassessment but does not independently determine the antiplatelet duration.

Clinical context

Dual antiplatelet therapy (DAPT), typically aspirin plus an oral P2Y12 inhibitor, reduces recurrent atherothrombotic events after acute coronary syndrome (ACS), but increases bleeding. For many ACS patients who are not at high bleeding risk and do not require long-term oral anticoagulation, 12 months of DAPT is the default strategy.

The default duration is not a one-size-fits-all prescription. Bleeding risk, recurrent ischemia, the ACS treatment pathway, procedural details, comorbidities, contraindications, adherence, and patient preferences should be reviewed. For ACS patients who require long-term oral anticoagulation after PCI, the 2025 ACC/AHA guideline recommends discontinuing aspirin after 1 to 4 weeks of triple therapy and continuing an oral anticoagulant plus a P2Y12 inhibitor, preferably clopidogrel. Timing and regimen must be individualized to the clinical setting and bleeding or ischemic risk.

This tool summarizes selected decision factors; it does not calculate a validated risk score and does not replace a complete clinical assessment.

Clinical disclaimer: Educational and documentation support only. Confirm decisions against current local and professional guidelines, the patient’s full clinical context, contraindications, and shared decision-making. Do not stop or modify antiplatelet or anticoagulant therapy solely on the basis of this tool.

Reference

Rao SV, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology. 2025. doi:10.1016/j.jacc.2024.11.009.